AGO2 protein: a key enzyme in the miRNA pathway as a novel biomarker in adrenocortical carcinoma
- Anila Hashmi 1,2, Alexander Papachristos 3,4, Stan Sidhu 3,4,5, Gyorgy Hutvagner 1
- Anila Hashmi 1,2, Alexander Papachristos 3,4, Stan Sidhu 3,4,5
- 1School of Biomedical Engineering, University of Technology Sydney, Sydney, New South Wales, Australia.
- 2NSW Health Pathology, Sydney, New South Wales, Australia.
- 3Endocrine Surgery Unit, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, New South Wales, Australia.
- 4Northern Clinical School, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
- 5Cancer Genetics Laboratory, Kolling Institute, Northern Sydney Local Health District, St. Leonards, New South Wales, Australia.
- 0School of Biomedical Engineering, University of Technology Sydney, Sydney, New South Wales, Australia.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study identifies AGO2 as a key miRNA processing gene overexpressed in adrenocortical carcinoma (ACC). Higher AGO2 levels predict poor survival, suggesting its potential as a diagnostic and prognostic biomarker for ACC.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Adrenocortical carcinoma (ACC) is an aggressive cancer with poor outcomes.
- Diagnostic and prognostic biomarkers for ACC are urgently needed.
- MicroRNA (miRNA) processing machinery plays a role in cancer development.
Purpose Of The Study
- To investigate the role of miRNA processing genes in ACC.
- To evaluate AGO2 as a potential diagnostic and prognostic biomarker for ACC.
Main Methods
- Analyzed mRNA expression of miRNA machinery genes (DROSHA, DGCR8, XPO5, RAN, DICER, TARBP2, AGO2) using TCGA and GTEx data.
- Quantified protein levels in ACC tissue samples.
- Performed Kaplan-Meier survival analysis.
Main Results
- AGO2 was significantly overexpressed in ACC compared to normal adrenal cortex and benign adrenal adenoma (P < 0.001).
- Higher AGO2 expression strongly correlated with worse overall survival in ACC patients (HR: 7.07, P < 0.001).
- AGO2's prognostic significance was most pronounced in ACC among 32 TCGA cancer types.
Conclusions
- AGO2 is a potential diagnostic and prognostic biomarker for adrenocortical carcinoma.
- AGO2's overexpression highlights its significance in ACC pathogenesis.
- AGO2 may serve as a non-invasive biomarker for ACC detection and monitoring.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
03:03
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
01:22
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

